PT  - JOURNAL ARTICLE
AU  - Bhattacharyya, Sudeepa
AU  - MahmoudianDehkordi, Siamak
AU  - Sniatynski, Matthew J
AU  - Belenky, Marina
AU  - Marur, Vasant R.
AU  - Rush, A. John
AU  - Craighead, W. Edward
AU  - Mayberg, Helen S.
AU  - Dunlop, Boadie W.
AU  - Kristal, Bruce S
AU  - Kaddurah-Daouk, Rima
AU  - ,
TI  - Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder
AID  - 10.1101/2024.04.02.24304677
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.02.24304677
4099  - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24304677.short
4100  - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24304677.full
AB  - Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive Behavior Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways. Changes in metabolite concentrations related to each treatment arm were identified and compared to define metabolic signatures of exposure. In addition, association between metabolites and depressive symptom severity (assessed with the 17-item Hamilton Rating Scale for Depression [HRSD17]) and anxiety symptom severity (assessed with the 14-item Hamilton Rating Scale for Anxiety [HRSA14]) were evaluated, both at baseline and after 12 weeks of treatment.Significant reductions in serum serotonin level and increases in tryptophan-derived indoles that are gut bacterially derived were observed with escitalopram and duloxetine arms but not in CBT arm. These include indole-3-propionic acid (I3PA), indole-3-lactic acid (I3LA) and Indoxyl sulfate (IS), a uremic toxin. Purine-related metabolites were decreased across all arms. Different metabolites correlated with improved symptoms in the different treatment arms revealing potentially different mechanisms between response to antidepressant medications and to CBT.Competing Interest StatementDr. Dunlop has received research support from, Boehringer Ingelheim, Compass, NIMH, and Usona Institute, and has served as a consultant to Biohaven, Cerebral Therapeutics, Myriad Neuroscience, and Otsuka. Dr. Craighead receives research support from the NIH; is a board member of Hugarheill ehf, an Icelandic company dedicated to the prevention of depression; receives book royalties from John Wiley; and is supported by the Mary and John Brock Foundation, the Pitts Foundation, and the Fuqua family foundations. He is a consultant to the George West Mental Health Foundation and a member of the Scientific Advisory Boards of AIM for Mental Health, Galen Mental Health, and the ADAA.A. John Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson and Johnson (Janssen), Liva-Nova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Rima Kaddurah-Daouk is an inventor on key patents in the field of Metabolomics and hold equity in Metabolon, a biotech company in North Carolina. In addition, she holds patents licensed to Chymia LLC and PsyProtix with royalties and ownership. All other authors reported no biomedical financial interests or potential conflicts of interest.Clinical TrialNCT00360399Funding StatementThis work was funded by grant support to Dr. Rima Kaddurah-Daouk (PI) through NIH grants R01MH108348, R01AG046171 and U01AG061359. Metabolomics data is provided by the Mood Disorders Precision Medicine Consortium (MDPMC). The MDPMC is led by Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. As such, the investigators within the MDPMC, not listed specifically in this publication's author's list, provided data along with its pre-processing and prepared it for analyses, but did not participate in analyses or writing of this manuscript. A complete listing of MDPMC investigators can be found at: https://sites.duke.edu/mdpmc/files/2020/12/MDPMC-Members-BD-RKD-11.24.2020.pdf. The PReDICT study was supported by NIH grants P50-MH077083 (PI Mayberg), R01-MH080880 (PI Craighead), UL1-RR025008 (PI Stevens), M01-RR0039 (PI Stevens) and the Fuqua family foundations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PReDICT study was conducted through the Mood and Anxiety Disorders Program of Emory University from 2007-2013 (Clinical trial NCT00360399 (08/04/2006) "Predictors of Antidepressant Treatment Response: The Emory CIDAR" https://clinicaltrials.gov/ct2/show/NCT00360399). The study was approved by the Emory Institutional Review Board. All patients provided written informed consent to participate. The study was conducted in accordance with the 1975 Declaration of Helsinki and its amendments.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.HRSA1414-item Hamilton Anxiety Rating ScaleHRSD1717-item Hamilton Depression Rating ScaleMDDMajor Depressive DisorderPReDICTPredictors of Remission in Depression to Individual and Combined Treatments study